Brief: Matinas BioPharma Reports Q4 Loss Per Share Of $0.03

Matinas BioPharma Holdings

29/03/2021 12:22

March 29 (Reuters) - Matinas BioPharma Holdings Inc
 MTNB.A :
    * MATINAS BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR
2020
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
    * Q4 LOSS PER SHARE $0.03
    * Q4 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES
DATA
    * MATINAS BIOPHARMA - ENROLLMENT CONTINUES IN SECOND PATIENT
COHORT OF ENACT STUDY OF MAT2203 IN CRYPTOCOCCAL MENINGITIS
    * MATINAS BIOPHARMA - DSMB REVIEW AND COHORT PROGRESSION IN
ENACT
STUDY OF MAT2203 IN CRYPTOCOCCAL MENINGITIS IS ANTICIPATED IN Q3
OF 2021
    * CASH ON HAND IS SUFFICIENT TO FUND OPERATIONS INTO 2024

Source text for Eikon:  ID:nGNX5sQHSy 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))